Loading
Life sciences · Journal article
Frontiers in Pharmacology · September 16, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
G protein-coupled receptors are among the largest protein superfamilies in the human genome and are responsible for sensing diverse extracellular signals and mediating them into cellular responses. Owing to their broad range of subunits and downstream effectors regulated by specific ligands, these receptors have been appealing pharmacological targets for the discovery of new drugs. Peptide agonists emerged as compelling treatment options for metabolic disorders, and many are currently used in therapy. This perspective comprehensively summarizes the medicinal chemistry efforts over the past 5 years toward the discovery of novel agonists targeting G protein-coupled receptors as promising, life-changing peptide therapies to treat metabolic disorders, like obesity and diabetes.